Struttura Semplice Dipartimentale di Oncologia Medica per la Presa in Carico Globale del Paziente Oncologico 'Don Tonino Bello', IRCCS Istituto Tumori 'Giovanni Paolo II', Viale Orazio Flacco 65, Bari, 70124, Italy.
Future Oncol. 2022 Jun;18(18):2301-2309. doi: 10.2217/fon-2021-1647. Epub 2022 Apr 5.
Stage I-III triple-negative breast cancer accounts for approximately 15-20% of new diagnoses of early breast cancer. Novel systemic treatment options have recently been assessed as part of the neoadjuvant approach, such as the addition of immune checkpoint inhibitors to cytotoxic chemotherapy. However, several questions remain unanswered, including the identification of predictors of response to immunotherapy in this setting, and further efforts aimed at identifying reliable predictors and clarifying the effective role of PD-L1 status, tumor mutational burden, tumor-infiltrating lymphocytes and other biomarkers are warranted. Herein we will provide an overview of recent clinical studies of neoadjuvant immune checkpoint inhibitors in patients with triple-negative breast cancer, especially focusing on the recently presented and published KEYNOTE-522, IMpassion031 and GeparNUEVO trials.
I 期-III 期三阴性乳腺癌约占早期乳腺癌新诊断病例的 15-20%。新的系统治疗方案最近已被评估为新辅助治疗的一部分，例如在细胞毒性化疗中加入免疫检查点抑制剂。然而，仍有几个问题尚未得到解答，包括确定该治疗环境下免疫治疗反应的预测因子，以及进一步努力确定可靠的预测因子并阐明 PD-L1 状态、肿瘤突变负担、肿瘤浸润淋巴细胞和其他生物标志物的有效作用。在此，我们将概述最近在三阴性乳腺癌患者中进行的新辅助免疫检查点抑制剂的临床研究，特别是重点介绍最近公布的 KEYNOTE-522、IMpassion031 和 GeparNUEVO 试验。
